Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1055/s-0035-1558185 http://scihub22266oqcxt.onion/10.1055/s-0035-1558185 C4771499!4771499!26941449     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Geburtshilfe+Frauenheilkd 2016 ; 76 (2): 164-9 Nephropedia Template TP {{tp|p=26941449|t=2016. PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives |pdf=|usr=}}{{26941449}} gab.com Text PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives JO: Geburtshilfe Frauenheilkd http://www.kidney.de/pget.php?&tw=1&pmid=26941449 #FOAvip More than simply a promising management option, PARP inhibitors can be regarded as a milestone in the development of personalised treatment of recurrent ovarian carcinoma. Their mechanism of action, known as ?synthetic lethality?, is dependent on functional differences of the DNA repair mechanisms of healthy cells and tumour cells; cells that repair DNA damage less efficiently are particularly sensitive to PARP inhibitors. Olaparib, licensed for use this year, is the best-studied PARP inhibitor used for treatment of high-grade serous ovarian carcinoma (HGSC). The efficacy of PARP inhibitors appears to be increased when used in combination with other treatments. Twit Text FOAVip PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives ????Geburtshilfe Frauenheilkd http://www.kidney.de/pget.php?&tw=1&pmid=26941449 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26941449 #FOAvip English Wikipedia <ref>{{Cite pmid|26941449}}</ref> PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives #MMPMID26941449 Sehouli J; Braicu EI; Chekerov R Geburtshilfe Frauenheilkd 2016[Feb]; 76 (2): 164-9 PMID26941449show ga More than simply a promising management option, PARP inhibitors can be regarded as a milestone in the development of personalised treatment of recurrent ovarian carcinoma. Their mechanism of action, known as ?synthetic lethality?, is dependent on functional differences of the DNA repair mechanisms of healthy cells and tumour cells; cells that repair DNA damage less efficiently are particularly sensitive to PARP inhibitors. Olaparib, licensed for use this year, is the best-studied PARP inhibitor used for treatment of high-grade serous ovarian carcinoma (HGSC). The efficacy of PARP inhibitors appears to be increased when used in combination with other treatments. äPARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Opt(epmc).pdf DeepDyve Pubget Overpricing